Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

UTD vs HER2.eSPR macrophage treatment in MC38.HER2 TIL

ABSTRACT: UTD vs HER2.eSPR macrophage treatment in MC38.HER2 TIL

PROVIDER: PRJNA1247289 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32999333_1.fastq.gz	Fastqsanger.gz
	SRR32999333_2.fastq.gz	Fastqsanger.gz
	SRR32999334_1.fastq.gz	Fastqsanger.gz
	SRR32999334_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

UTD vs HER2.eSPR macrophage treatment in MC38.HER2 TIL

Project description:Here, exploiting myeloid antibody-dependent cellular phagocytosis biology and phagocytosis checkpoint blockade, we report an enhanced synthetic phagocytosis receptor (eSPR) that integrates FcRγ-driven phagocytic chimeric antigen receptors (CARs) with built-in secreted CD47 blockers. To assess modulation of the tumor immune microenvironment by eSPR macrophages, untreated (UTD) and eSPR-macrophage-treated tumor tissues were extracted and processed. CD45⁺ tumor-infiltrating leukocytes were sorted and analyzed by single-cell RNA sequencing.

2025-04-26 | GSE293891 | GEO

Macrophage phenotype in anti-PD-L1 treated MC38 tumors

Project description:Macrophage phenotype in anti-PD-L1 treated MC38 tumors

| PRJNA516065 | ENA

Immunopeptidome on MC38 Cell line

Project description:PTM – driven antigenicity – immunopeptidome of MC38 cell line

2022-10-12 | PXD017448 | Pride

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial

Project description:Biopsy samples from 4 sites were collected for RNA-Seq and single-cell RNA-Seq from patients with HER2 positive tumors enrolled in a Phase 1 clinical trial of anti-HER2 CAR-macrophage cell therapy. Biopsies of solid tumors were aimed to be collected at screening, 8 days after treatment, and 4 weeks after treatment. Patients in Group 1 received dose escalation of intravenous administration of up to 500 million cells, 1.5 billion cells, and 3 billion cells, on Day 1, 3, and 5, respectively. Patients in Group 2 received their full dose of cells on Day 1. This trial aimed to determine the feasibility of manufacturing CAR-macrophages, as well as assess the safety and tolerability of CAR-macrophage therapy, and determine the severity of potential adverse events.

2025-03-01 | GSE285746 | GEO

RNA-sequencing on sorted infiltrating CD8 T cells from vehicle or JHU083, pro-drug of 6-Diazo-5-oxo-L-norleucine (glutamine antagonist) treated MC38 (colon cancer) tumor bearing mice

Project description:RNA-sequencing was performed on sorted CD11b-CD11c-B220-CD45+TCRbeta+CD44+CD8+ TIL from vehicle or JHU083 treated MC38 tumor-bearing mice with or without JHU083, pro-drug of 6-Diazo-5-oxo-L-norleucine (glutamine antagonist) treatment for expression profiling

2020-02-24 | GSE120345 | GEO

RNA-seq of parental MC38 and anti-PD-1 resistant MC38 subcutaneous tumors

Project description:MC38 tumors resistant to anti-PD-1 treatment (MC38-resistant) were generated through serial in vivo passaging, and global gene expression analysis was used to compare resistant and parental tumors. MC38 and MC38-resistant tumors exhibited widespread changes in global gene expression.

2021-07-22 | GSE180309 | GEO

Macrophage-specific Act1 Knockdown Promoted Adenoma-Adenocarcinoma Transition in Apcmin+/- Mice via Activation of the CXCL9/10-CXCR3 axis

Project description:macrophages involve in colorectal adenocarcinoma transition. Mouse MC38 colorectal cancer cells were co-cultured with BMDM from both anti-Act1 and Wildtype mice. MC38 cells have higher migration speed and express higher EMT markers including Snail, E-cadherins, and Twist after co-culture with anti-Act1 macrophage. Expression profiling by high throughput sequencing highlighted that by co-culturing with MC38 cells, anti-Act1 macrophage increase proinflammatory cytokines secretion and consequently activates cytokines receptor signaling pathway. Specifically, we identified the mechanism where CXCL9/10 from anti-Act1 macrophage interacted with CXCR3 receptor in MC38 cell to promote MC38 migration as well as EMT. Besides, coculturing with MC38 cells enhanced expressions of PD-L1 and MDSCs markers such as Arg1, iNOS, IDO1 in anti-Act1 macrophages. Among activating pathways, we reveal that anti-Act1 macrophage orchestrates NF-kB and STAT3 signaling pathways to upregulate CXCL9/10 secretion and PD-L1 expression. These findings demonstrate that anti-Act1 in macrophage induced a significant shift in MC38 cells gene expression, and modulating the macrophage-cancer is a viable strategy to assist PD-L1 immunotherapy.

2022-09-01 | GSE183971 | GEO

Single-cell RNA-seq of MC38 tumor model

Project description:Single-cell RNA-seq was performed on CD45+ and T cells sorted from MC38 tumors from mice.

2024-12-06 | E-MTAB-14590 | biostudies-arrayexpress

Photoconversion of MC38

Project description:Photoconversion of MC38

| PRJNA797079 | ENA

Transcriptomic profiling of MC38 tumor cells on murine MC38 liver metastasis sections by NanoString GeoMX DSP

Project description:To study how targeting CMTM6 inCRCs influences the transcritome. Control MC38 and CMTM6-deficient MC38 were subjected to spatial transcriptomic profiling with the NanoString GeoMx DSP

2025-06-11 | GSE253937 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data